Seer, Inc. [NASDAQ: SEER] has inked a commercial agreement with SCIEX to offer end-to-end unbiased proteomics solutions. As per the agreement, Seer will be able to market SCIEX mass spectrometry systems combined with its Proteograph Product Suite.
The merged product offering will allow labs of all types to integrate highly sensitive mass spectrometry with impartial, deep proteomic research studies at scale, providing new levels of understanding, speed, and sensitivity. The Proteograph Product Suite included Seer’s patented engineered nanoparticles, consumable products, an automation tool, and software that allow proteomics analyzes with a remarkable combination of speed, scale, depth, and scope of data.
Shares of Seer soared 2.17% at $41.05 during the trading session of Monday. In the past 52-weeks of trading, the firm share went up 6.98% from its 52-week low and went down -52.57% from its 52-week high. Focusing on its liquidity, it has a current ratio of 21.00. Seer has a total market capitalization of $2.60 billion at the time of writing.
Seer is delighted to cooperate with SCIEX, and the firm is striving to pave the way for the labs to broaden their proteomics discovery efforts. The firm aimed to help all labs to include neutral proteomics in their studies. Seer and SCIEX are planning to the future cooperation, such as through creating centers of brilliance utilizing both technologies, enhancing the workflow for key applications, and supporting development efforts.